You are here

Singapore-based firm on track to commercialise cancer drug

Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020

BT_20170629_JUCANCER29_2956239.jpg
Tessa Therapeutics' chief scientific officer John Connolly with his team in the lab Tessa shares with the Institute of Molecular and Cell Biology. Tessa has teamed up with the Parker Institute for Cancer Immunotherapy in California to advance immunotherapy research.

Singapore

SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.

A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of

sentifi.com

Market voices on:

Powered by GET.comGetCom